Angina Pectoris with Troponin Increase in Arrhythmogenic Right Ventricle Dysplasia: Case Article and Review of the Literature
Division of Pediatric Cardiology, Penn State Hershey Medical College, Hershey, PA 17033, USA. Pediatric Cardiology
(Impact Factor: 1.31).
01/2012; 33(4):659-62. DOI: 10.1007/s00246-012-0174-2
A 16-year-old Hispanic girl with arrhythmogenic right-ventricle dysplasia (ARVD) presented with angina pectoris and troponin increase on three occasions. There was a family history of sudden cardiac death in a cousin. Her mother was diagnosed with ARVD. The patient herself had a history of nonsustained ventricular tachycardia but did not meet diagnostic criteria for ARVD. Cardiac workup, including serial transthoracic echocardiograms and a coronary angiogram, showed a structurally normal heart without coronary artery stenosis. Results of cardiac magnetic resonance imaging were questionable, but endomyocardial biopsy did not show evidence of viral myocarditis by polymerase chain reaction. Genetic testing confirmed ARVD.
Available from: Agnieszka Noszczyk-Nowak
[Show abstract] [Hide abstract]
ABSTRACT: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is described as a disease that has an autosomal dominant trait with reduced penetrance, that appears in dogs between two and eight years of age. Boxers are predisposed to ARVC. Some of the symptoms of ARVC are fainting, attacks of tachycardia - especially vetnricular tachycardia and sudden cardiac death. The aim of the study was to estimate the usefulness of 24-h Holter monitoring and the level of troponin I (cTnI) in examining the treatment of Boxers with ARVC. 24-h Holter monitoring and plasma concentrations of cTnI were carried out every three months after introducing anti-arrhythmic treatment (metoprolol prolongatum, sotalol or amiodaron). There was a significant correlation between the number of ventricular premature complexes (VPC) over a 24-h period and the level of cTnl. No correlation was found between the appearance of monitoring ventricular tachycardia (VT) and the level of cTnI. The presented results show the possibility to use cTnl to evaluate the efficacy of antiarrhythmia treatment in dogs with ARVC.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.